This article is available to subscribers. Sign in or Subscribe.

Review ArticleMedical ProgressFree Preview

Amyotrophic Lateral Sclerosis

  • Lewis P. Rowland, M.D.,
  • and Neil A. Shneider, M.D., Ph.D.

This article has no abstract; the first 100 words appear below.

Charcot described amyotrophic lateral sclerosis (ALS) in 1874. Despite progress, this creeping paralysis, known colloquially as Lou Gehrig's disease, is still not visibly affected by available therapies. However, advances in genetics have accelerated the pace of ALS research in the past decade, promising more effective treatment.Definition of the DiseaseALS has two meanings. In one sense, it refers to several adult-onset conditions characterized by progressive degeneration of motor neurons (Figure 1). In the United Kingdom, the term motor neuron disease is used for these disorders. In the second sense, ALS refers to one specific form of motor neuron disease . . .

Funding and Disclosures

Dr. Shneider is the recipient of a Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physicians and a Mentored Clinical Scientist Career Development Award (K08) from the National Institute of Neurological Disease and Stroke.

Author Affiliations

From the Eleanor and Lou Gehrig MDA/ALS Center, Neurological Institute, Columbia–Presbyterian Medical Center, New York–Presbyterian Hospital, and Columbia University College of Physicians and Surgeons — all in New York.

Address reprint requests to Dr. Rowland at the Neurological Institute, Columbia–Presbyterian Medical Center, 701 W. 168th St., New York, NY 10032, or at .

Purchase this article
Print Subscriber? Activate your online access.